Publication

Poster presented at the 10th Immunoglobulin National Society Conference (IgNS) 2021

Efficacy and Safety of PlasmaCap® IG (Immunoglobulin) Poster

22nd Oct 2021 – Las Vegas, NV (October 22nd, 2021) – Evolve presented updated results on behalf of Dr Richard Wasserman from the completed PlasmaCap IG Phase III Clinical Trial entitled “Efficacy and Safety of PlasmaCap IG, a New 10% Intravenous Immunoglobulin Manufactured Using an Innovative Chromatography Process, In Adults and Children with Primary Immunodeficiency Disorders”

Publication

Poster presented at Clinical Immunology Meeting (CIS) April 2021

Efficacy and Safety of PlasmaCap® IG poster

16 Apr, 2021 – Virtual Meeting (April 16, 2021) – Dr Richard Wasserman presented results from the completed PlasmaCap IG Phase III Clinical Trial entitled “Efficacy and Safety of PlasmaCap IG, a New 10% Intravenous Immunoglobulin Manufactured Using an Innovative Chromatography Process, In Adults and Children with Primary Immunodeficiency Disorders”. Abstracts available here

Publication

Poster Presented at IgNS October 2019

PlasmaCap® IG (Immunoglobulin) Poster

25 Oct, 2019 – Las Vegas, NV (October 25, 2019) – Evolve presented “Interim results of a novel 10% liquid intravenous immune globulin (IVIG) product’s Phase III Prospective, Open-Label Multicenter Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics in Adults and Children with Primary Immunodeficiency Disease (PIDD)”. Abstracts available here.

Publication

Poster Presented at AAAAI February 2019

PlasmaCap™ IG (Immunoglobulin) Poster

24 Feb, 2019 – San Francisco, CA (February 24, 2019) – Dr Richard Wasserman presented “Interim Safety Data in a Prospective, Open-Label, Multi-Center Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of PlasmaCap IG in Patients with Primary Immunodeficiency Diseases (PIDDs)”. Abstract published in Journal of Allergy Clinical Immunology (JACI).

Publication

Posters Presented at IgNS October 2018

PlasmaCap EBA™ Technology Poster
PlasmaCap™ IG (Immunoglobulin) Clinical Trial Poster

19 Oct, 2018 – Dallas, TX (October 19, 2018) – Evolve presented “A prospective, open-label, multicenter study of the efficacy, safety, tolerability, and pharmacokinetics of PlasmaCapTM IG (Immunoglobulin) in adults and children with primary immunodeficiency” and “PlasmaCap EBA™, an innovative method of isolating plasma proteins from human plasma”. Abstracts available here.